Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables (2016 - 2025)

Historic Change in Receivables for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to $117491.0.

  • China Pharma Holdings' Change in Receivables fell 2977.18% to $117491.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $515669.0, marking a year-over-year increase of 4774.6%. This contributed to the annual value of $197708.0 for FY2024, which is 7892.29% down from last year.
  • China Pharma Holdings' Change in Receivables amounted to $117491.0 in Q3 2025, which was down 2977.18% from $20566.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Change in Receivables registered a high of $434306.0 during Q1 2023, and its lowest value of -$258130.0 during Q1 2022.
  • Moreover, its 5-year median value for Change in Receivables was $117491.0 (2025), whereas its average is $113378.1.
  • In the last 5 years, China Pharma Holdings' Change in Receivables crashed by 33094.88% in 2021 and then surged by 57817.13% in 2022.
  • Quarter analysis of 5 years shows China Pharma Holdings' Change in Receivables stood at $393662.0 in 2021, then tumbled by 72.75% to $107286.0 in 2022, then skyrocketed by 239.52% to $364258.0 in 2023, then plummeted by 41.54% to $212942.0 in 2024, then plummeted by 44.82% to $117491.0 in 2025.
  • Its Change in Receivables was $117491.0 in Q3 2025, compared to $20566.0 in Q2 2025 and $164670.0 in Q1 2025.